Global News

Shire’s retinopathy treatment fails phase II trial

Monday, July 4, 2016

Shire has announced that its phase II study evaluating an investigational protein replacement, SHP607, did not meet its primary endpoint of reducing the severity of retinopathy of prematurity (ROP), a rare eye condition. The study, however, demonstrated clinically relevant effects in secondary endpoints related to the development of severe bronchopulmonary dysplasia (BPD), a chronic lung disease, and severe intraventricular hemorrhage (IVH), a type of brain injury, both of which have lifelong negative implications for normal development. 

[Read More]

ICON to acquire Clinical Research Management

Thursday, June 30, 2016

Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has agreed, subject to certain customary closing conditions (including applicable regulatory approvals), to acquire Clinical Research Management (ClinicalRM). The acquisition will enhance Icon’s ability to access the market for government sponsored research and further enhances Icon’s capabilities in the areas of Vaccines and Infectious Disease.

[Read More]